BLUA vs. ALUR, BWAY, KRMD, STIM, TELA, NVNO, SEPA, MGRM, SRTS, and PDEX
Should you be buying BlueRiver Acquisition stock or one of its competitors? The main competitors of BlueRiver Acquisition include Allurion Technologies (ALUR), BrainsWay (BWAY), KORU Medical Systems (KRMD), Neuronetics (STIM), TELA Bio (TELA), enVVeno Medical (NVNO), SEP Acquisition (SEPA), Monogram Orthopaedics (MGRM), Sensus Healthcare (SRTS), and Pro-Dex (PDEX). These companies are all part of the "surgical & medical instruments" industry.
BlueRiver Acquisition (NYSE:BLUA) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.
Allurion Technologies has a consensus target price of $5.00, suggesting a potential upside of 182.49%. Given Allurion Technologies' higher possible upside, analysts clearly believe Allurion Technologies is more favorable than BlueRiver Acquisition.
BlueRiver Acquisition has higher earnings, but lower revenue than Allurion Technologies.
BlueRiver Acquisition has a net margin of 0.00% compared to Allurion Technologies' net margin of -117.30%.
Allurion Technologies received 3 more outperform votes than BlueRiver Acquisition when rated by MarketBeat users.
In the previous week, Allurion Technologies had 12 more articles in the media than BlueRiver Acquisition. MarketBeat recorded 13 mentions for Allurion Technologies and 1 mentions for BlueRiver Acquisition. Allurion Technologies' average media sentiment score of 0.31 beat BlueRiver Acquisition's score of 0.00 indicating that Allurion Technologies is being referred to more favorably in the news media.
22.3% of BlueRiver Acquisition shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 79.0% of BlueRiver Acquisition shares are owned by insiders. Comparatively, 20.0% of Allurion Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Allurion Technologies beats BlueRiver Acquisition on 6 of the 11 factors compared between the two stocks.
Get BlueRiver Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BlueRiver Acquisition Competitors List
Related Companies and Tools
